[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endemic-mycoses\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endemic-mycoses":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100654891","phase-2-platform-trial-for-salvage-consolidation-therapy-in-dimorphic-fungi-100654891",false,"NCT07804368","Platform Trial for Salvage Consolidation Therapy in Dimorphic Fungi","Inclusion Criteria:\n\n* Diagnosis of coccidioidomycosis, blastomycosis, or histoplasmosis and on active therapy\n* Age 18 years or older\n* Anticipated need for at least 6 additional months of antifungal therapy at enrollment\n* Intolerance, failure, or unavailability of current first-line consolidation therapy\n\nExclusion Criteria:\n\n* Currently hospitalized\n* Central nervous system involvement of coccidioidomycosis, blastomycosis, or histoplasmosis\n* Previous administration of or allergy to study drug\n* Any condition for which participation would not be in the best interest of the participant or that could limit protocol-specified assessments\n* Females of childbearing potential\n* Breast Cancer Resistance Protein substrate medication interaction that cannot be managed by switching medication, discontinuation, 50% dose reduction, or use of the lowest dose\n* Children\n* Pregnant women\u002Fpersons\n* Fetuses\n* Neonates\n* Prisoners\n* Adults lacking capacity to consent or adults with diminished or fluctuating capacity to consent","ALL","18 Years",{"count":18,"type":19},30,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","This Phase II platform trial will evaluate the safety, tolerability, and effectiveness of investigational antifungal agents as salvage or consolidation therapy in adults with dimorphic fungal infections, including coccidioidomycosis, blastomycosis, and histoplasmosis.\n\nThe study will enroll adults who are receiving active antifungal therapy and who have intolerance, failure, or unavailability of standard first-line consolidation therapy. The first investigational agent evaluated in the platform trial is oteseconazole.\n\nParticipants will receive study drug and complete follow-up assessments for symptom status, functional status, adverse events, laboratory safety, study drug discontinuation, and quality of life. Participants will be followed during therapy and for up to 6 months after therapy.",[25,26,27,28,29],"Coccidioidomycosis","Blastomycosis","Histoplasmosis","Dimorphic Fungal Infection","Endemic Mycoses",[31,32,33,25,34],"Dimorphic fungi","Endemic mycoses","Salvage therapy","Antifungal therapy","NOT_YET_RECRUITING","2026-08-31",{"date":38,"type":39},"2026-09-04","ACTUAL",{"date":41,"type":19},"2026-12-01",{"date":43,"type":19},"2028-12-01",{"name":45,"class":46},"University of Minnesota","OTHER",4]